



April 8, 2015

## Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference

SAN DIEGO, April 8, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:10 pm EDT in New York, NY.

A live webcast of the presentation will be available through the investor relations section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.

### About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. The Company's approach utilizes established pharmacologic modalities, such as small molecules, to program the fate and function of cells *ex vivo*. The Company's lead product candidate, PROHEMA®, is an *ex vivo* programmed hematopoietic cellular therapeutic, which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation (HSCT). The Company is also using its proprietary induced pluripotent stem cell platform to develop *ex vivo* reprogrammed hematopoietic and myogenic cellular therapeutics. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

CONTACT: Jesse Baumgartner, Stern Investor Relations, Inc.

212.362.1200, [jesse@sternir.com](mailto:jesse@sternir.com)